Tag Archive for: eosinophilic esophagitis (EoE)

Takeda Pharmaceutical’s therapy for an allergic inflammation of the esophagus has received approval from the U.S. FDA, the Japanese drugmaker said on Monday, capping a years-long regulatory process.

Data from an ongoing Phase III trial showed Sanofi/Regeneron’s Dupixent (dupilumab) can induce histological disease remission in young eosinophilic esophagitis (EoE) patients ages 1–11 years, the companies announced Tuesday.

In the latest win for Regeneron Pharmaceuticals and Sanofi’s Dupixent (dupilumab), the partners announced positive results from a Phase III trial of the blockbuster in kids ages one to 11 years with eosinophilic esophagitis (EoE).